Here are four recent cancer care and research-related partnerships and affiliations formed since May 11.
The Latest
Throughout the past year, 70 percent of oncologists surveyed reported some form of sexual harassment by their peers or superiors, according to findings recently published in the Journal of Clinical Oncology.
AstraZeneca's Lynparza drug cut the combined risk of recurrence of cancer or death from any cause by 42 percent among early-stage breast cancer patients with certain mutations, compared to those who received a placebo, according to research published June 3…
The Sidney Kimmel Cancer Center in Philadelphia, part of Jefferson Health, has named Andrew Aplin, PhD, as deputy director of scientific strategy.
The National Cancer Institute removed Axel Grothey, MD, from his position as co-chair of a steering committee May 27 after reports surfaced that the physician had inappropriate sexual relationships with mentees while working at Rochester, Minn.-based Mayo Clinic, Medscape reported…
In an era of infinite challenges and finite resources, health systems must employ a rigorous approach to strategic and facility planning. This is particularly true for oncology, where the pace of change and innovation is unprecedented.
An odor-based test developed by researchers at the University of Pennsylvania's medical school in Philadelphia identified cancer cells with up to 95 percent accuracy, according to findings set to be presented June 4 at the 2021 American Society of Clinical…
Biosimilars are FDA-approved medicines that are rigorously tested and subject to the same quality manufacturing standards as reference medicines.
A story about an influx of progressing cancer diagnoses that slipped through the cracks amid earlier stages of the pandemic was Becker's most-read oncology story in May.
Healthcare in the US is often a double-edged sword. Recently, it’s gotten sharper at both ends.